Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Seres Therapeutics (MCRB) over the last 5 years, with Dec 2024 value amounting to $155.4 million.

  • Seres Therapeutics' Shares Outstanding (Diluted Average) rose 19.30% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 19.30%. This contributed to the annual value of $155.4 million for FY2024, which is 21.40% up from last year.
  • Latest data reveals that Seres Therapeutics reported Shares Outstanding (Diluted Average) of $155.4 million as of FY2024, which was up 21.40% from $128.0 million recorded in FY2023.
  • Seres Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $155.4 million for FY2024, and its period low was $79.8 million during FY2020.
  • For the 3-year period, Seres Therapeutics' Shares Outstanding (Diluted Average) averaged around $130.5 million, with its median value being $128.0 million (2023).
  • Data for Seres Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increased of 21.40% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Seres Therapeutics' Shares Outstanding (Diluted Average) stood at $79.8 million in 2020, then climbed by 14.93% to $91.7 million in 2021, then grew by 17.86% to $108.1 million in 2022, then increased by 18.44% to $128.0 million in 2023, then grew by 21.40% to $155.4 million in 2024.